The FDA has approved Phase I and II clinical trials of CRISPR/Cas technology for HIV treatment.
The intravenous CRISPR/Cas technology was developed by Excision BioTherapeutics and will begin clinical trials in late 2021. During the work, the researchers will evaluate the effectiveness of different dosages of the drug on three groups of HIV-infected volunteers.
During infection, HIV is embedded in the DNA of cells, so so far no effective ways to get rid of it have been invented. The CRISPR/Cas gene editing technology could be an effective method of fighting HIV, as it excises the virus directly from the genome
In clinical trials, doctors will test a technology that targets the human immunodeficiency virus: a drug called EBT-101. The researchers want to find out which combinations of CRISPR / Cas therapy and other therapies will be most effective.
For now, it’s too early to say that HIV has been defeated, since scientists still need to prove not only the effectiveness of treatment with the CRISPR/Cas system, but also its safety.